VolitionRx Limited

VNRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $1.7M $1.2M $775.3K $306.4K $90.0K $13.4K $17.1K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $10.1M $14.4M $19.6M $15.3M $13.0M $14.5M $10.4M
SG&A Expense $9.5M $8.5M $10.4M $10.2M $11.7M $5.7M $4.7M
Operating Income $-21.7M $-27.0M $-36.0M $-31.8M $-28.3M $-21.2M $-16.0M
Operating Margin -1,258.5% -2,190.9% -4,641.8% -10,372.4% -31,469.0% -158,176.2% -93,840.2%
Interest Expense $155.8K $129.8K $126.6K
Pretax Income
Income Tax Expense
Net Income $-23.4M $-27.0M $-35.7M $-30.6M $-27.0M $-20.4M $-16.1M
Net Margin -1,352.2% -2,186.3% -4,601.7% -9,986.7% -29,977.0% -151,859.6% -94,168.5%
EPS (Basic) $-0.51 $-0.45 $-0.41
EPS (Diluted) $-0.31 $-0.50 $-0.51 $-0.45 $-0.41
Shares Outstanding (Basic) 8.1M 57.9M 53.8M 48.6M 41.1M
Shares Outstanding (Diluted) 8.1M 106.8M 86.5M 71.2M 57.9M 53.8M 48.6M 41.1M
Dividends Per Share
← Newer Page 1 of 3 Older →